ArticleOncotarget2018
Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- A Comparative Meta-Analysis andFrontiers in veterinary science · 2020Pooled it
- Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for epidermal growth factor receptor-expressing advanced solid tumors: a scoping review of barriers and enablers to clinical translation.Antibody therapeutics · 2026Review
- Prediction of the photodynamic therapy effect using digital breast phantoms from patients with breast cancer via Monte Carlo simulations.Journal of biomedical optics · 2025Article
- Targeted Elimination of Influenza Virus and Infected Cells with Near-Infrared Antiviral Photoimmunotherapy (NIR-AVPIT).Pharmaceutics · 2025Article
- Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review.Cancer management and research · 2025Review
- Photodynamic Therapy for Bladder Cancers, A Focused ReviewPhotochemistry and photobiology · 2023Review
- Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.International journal of molecular sciences · 2023Review
- Article
- Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in dogs with lower urinary tract urothelial carcinoma.BMC veterinary research · 2022Article
- Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective.Biomedicines · 2022Review
- Review
- Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.Biomedicines · 2022Review
- Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.BMC medicine · 2022Article
- Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.Theranostics · 2022Review
- Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.Oncotarget · 2022Article
- Near infrared photoimmunotherapy of cancer; possible clinical applications.Nanophotonics (Berlin, Germany) · 2021Review
- Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic.Nanophotonics (Berlin, Germany) · 2021Article
- Review
- Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes.Cancer science · 2021Article
- Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
Anti-epidermal growth factor receptor (EGFR) antibody therapy is used in EGFR expressing cancers including lung, colon, head and neck, and bladder cancers, however results have been modest. Near infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that employs an antibody-photo-absorber conjugate which is activated by NIR light. NIR-PIT is in clinical trials in patients with recurrent head and neck cancers using cetuximab-IR700 as the conjugate. However, its use has otherwise been restricted to mouse models. This is an effort to explore larger animal models with NIR-PIT. We describe the use of a recombinant canine anti-EGFR monoclonal antibody (mAb), can225IgG, conjugated to the photo-absorber, IR700DX, in three EGFR expressing canine transitional cell carcinoma (TCC) cell lines as a prelude to possible canine clinical studies. Can225-IR700 conjugate showed specific binding and cell-specific killing after NIR-PIT on EGFR expressing cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.